Exavir Therapeutics Announces Publication of Preclinical Data on Ultra-Long-Acting… | New

Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species

Injections were well tolerated with no adverse findings in preliminary toxicology analyzes and injection site histopathology

SAN FRANCISCO and OMAHA, Neb., June 09, 2022 (GLOBE NEWSWIRE) — Exavir Therapeutics, a company dedicated to transforming the lives of patients living with or at risk of HIV and other viral infections, today announced the publication of preclinical data for XVIR-120, an investigational agent under development as a long-acting injectable antiviral for the treatment and prophylaxis of HIV.

The research results were published today in Nature Communication in an article titled ” Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation “, and detailed plasma pharmacokinetics, tissue biodistribution, and injection site histology of XVIR-120, a novel nanoformulated prodrug of dolutegravir, through preliminary studies in rodents and non-human primates that demonstrate that injections were well tolerated and support ultra-long acting dosing intervals.

“Dolutegravir is an important drug for HIV patients, with more than 17 million people worldwide on daily oral therapy today,” said Howard Gendelman, scientific co-founder of Exavir Therapeutics. “We look forward to leveraging the existing safety and efficacy database for this compound and rapidly delivering our proprietary ultra-long-acting prodrug formulation.”

“Exavir has generated strong preclinical data in several programs that strongly reduce risk for the development of ultra-long-acting antiretroviral therapy,” said Dr. John C. Pottage Jr., Scientific Advisor to Exavir Therapeutics. “I am thrilled to be part of the team and to help bring these drugs into the clinic. Long-acting is clearly the way of the future in HIV treatment and prophylaxis.”

Dr. Pottage is the former Chief Scientific Officer (CSO) and Chief Medical Officer (CMO) of ViiV Healthcare, and was responsible for the development of several antiviral drugs, including dolutegravir and cabotegravir, the first long-acting injectable drug approved for HIV.

About Exavir Therapeutics, Inc.

Exavir Therapeutics is a preclinical-stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-neutral approach, beginning with long-acting antiviral therapies.

HIV is one of the most serious public health problems in the world. It is estimated that there are over 37 million people living with HIV worldwide and nearly 1.2 million people living with HIV in the United States alone. More than 30 billion dollars are spent each year on antiretroviral therapy for HIV worldwide.


For requests:

[email protected]

Source: Therapeutic Exavir

Copyright 2022 GlobeNewswire, Inc.

Jacob L. Thornton